FDA D.I.S.C.O. Burst Edition: FDA approval of Retevmo (selpercatinib) for advanced or metastatic ...
Follow
Listen to a soundcast of the May 29, 2024, FDA approval of Retevmo (selpercatinib) for patients with advanced or metastatic RET fusionpositive thyroid cancer who require systemic therapy and who are radioactive iodinerefractory.